You are here

Craig Strathdee


Goldstein JT, Berger AC, Shih J, et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 2017 Dec 15;77(24):6987-6998.

Hua Z, Huang X, Bregman H, et al. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. Bioorg Medicinal Chem Lett. 2012;22(17):5392–5395.

Huang H, Acquaviva L, Berry V, et al. Structure-based design of potent and selective CK1γ inhibitors. ACS Med Chem Lett. 2012;3(12):1059–1064.

Craig Strathdee, Ph.D.

Craig Strathdee is a senior group leader in the Cancer Program at the Broad Institute of MIT and Harvard. Under the direction of Matthew Meyerson, Strathdee leads a group responsible for validating and prosecuting drug targets that have emerged from the Broad Institute's comprehensive oncogenomics efforts. His approach to target validation utilizes RNAi, CRISPR, and ORF expression platforms to genetically perturb candidate target gene expression in relevant cancer cell lines, and then profile the resulting phenotypic changes with regard to their effect on various biochemical pathways. Following target validation, Strathdee’s group leads the biological aspects of each drug discovery project and is responsible for the identification and implementation of suitable cell-based screens to support the subsequent high throughput screening, as well as guiding the design of a corresponding assay cascade to support follow-on hit expansion and lead optimization efforts.

Strathdee joined the Broad Institute in 2013 and has a diverse research background. He started his career as an assistant professor and principal investigator at the Robarts Research Institute at the University of Western Ontario, working in the nascent field of gene therapy. He then moved on to industry, where he developed his oncology drug discovery skills while working as a director and research scientist at Immunex and Amgen for 11 years.

Strathdee earned his Ph.D. in microbial pathogenesis and B.Sc. in microbiology from the University of Guelph, with further postdoctoral training in human genetics at the Hospital for Sick Children of the University of Toronto.

Contact Craig Strathdee via email at

January 2019